ClinicalTrials.gg
RecruitingNCT07337889TLURUpdated Jun 22, 2026

Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder

An interventional study of Relationship-use questionnaire in Borderline Personality Disorder, Borderline Personality Disorder (BPD) and Bipolar Disorder (BD), sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
194
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Borderline Personality Disorder with a site in France — 12 open to participants now, 13 under way, none of them phase 3. Borderline Personality Disorder · France.

Planned enrollment
6th of 24
194 · median 72
Started
2026
with 2 others
No phase
20 of 32
9 open now
Primary completion
2028-04
later than 8 of 12 live
Registered
29th of 32
by date
Lead sponsor
7 of 32
University Hospital, Montpellier

Among the 32 studies in Borderline Personality Disorder with a site in France, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 20 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 29th registered.

Borderline Personality Disorder

279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

12 of the 32 studies in Borderline Personality Disorder with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Borderline Personality Disorder with a site in France, or all of them as a file.
02

Study summary

This study aims to explore a novel conceptualization of Borderline Personality Disorder (BPD) as a "Relationship Use Disorder." The research proposes that BPD shares key features with behavioral addictions, specifically addiction to interpersonal relationships. The study builds upon previous findings suggesting that individuals with BPD experience intense emotional dysregulation, including negative self-perception, shame, and a compulsive need for external validation. This addiction to relationships, much like substance use disorders, is thought to contribute significantly to the difficulties faced by these individuals, including interpersonal conflicts, self-destructive behaviors, and emotional instability.

The study seeks to demonstrate that the relational difficulties central to BPD meet the diagnostic criteria for addiction as defined by the DSM-5. It will also explore how these relational struggles are mediated by dysfunctional self-perception and whether they are linked to behaviors such as compulsive sexual behaviors (CSBD) or suicidal tendencies. Additionally, the research will investigate the relationship between addiction to relationships and neurobiological factors, including endorphin levels, in individuals with BPD compared to those with bipolar disorder and healthy controls. The hypothesis is that individuals with BPD will exhibit higher levels of relationship addiction, with this addiction being tied to their perception of self-worth and emotional experiences in relationships.

This innovative approach aims to refine the understanding of BPD, reduce stigma, and improve treatment strategies by providing scientific evidence supporting the conceptualization of BPD as a "Relationship Use Disorder."

03

Conditions studied

  • Borderline Personality Disorder
  • Borderline Personality Disorder (BPD)
  • Bipolar Disorder (BD)

Keywords

  • borderline personality disorder
  • relationship-use disorder
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General : aged 18-45
  • Specific :
  • Borderline personality disorder (BPD)assessed by SCID, without bipolar disorder
  • Bipolar disorder (assessed by SCID), without BPD (evaluated by SCID)
  • Healthy controls with no psychiatric disorders (screened by SCID).

Exclusion criteria

Exclusion Criteria:

  • Psychotic disorders (evaluated by SCID)
  • lack of
  • Not affiliated with social security
  • Under judicial or administrative confinement or involuntary hospitalization
  • Protected by law (e.g., under guardianship)
  • Pregnancy or breastfeeding
  • Inability to understand, speak, or write in French
  • Inability to understand the study's purpose or methodology
  • Excluded from another study during the exclusion period
  • Participants who have received over €6000 in annual indemnities
  • For Bipolar Participants (without BPD) : Current moderate or severe depressive episode (BDI score > 18) or Current hypomanic/manic episode (YMRS \< 12)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    Patients with borderline personality

    Patients with borderline personality disorder without bipolar disorder

    Other: Relationship-use questionnaire

  • Experimental
    Patients with bipolar disorder

    patients with bipolar disorder without borderline personality disorder

    Other: Relationship-use questionnaire

  • Experimental
    Healthy controls

    Healthy controls (i.e. without psychiatric disorders), from the general population

    Other: Relationship-use questionnaire

Interventions

  • OtherRelationship-use questionnaire

    Questionnaire adapted from the 'Substance Use Disorders' section of the DSM-5: Disorder related to the use of close relationships

06

What researchers measure

Primary outcomes

  1. Relational Addiction

    Using the experimental relationship-use questionnaire based on the DSM-5 Substance Use Disorder items among patients with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD, and healthy controls.

    Time frame: Measured at baseline

Secondary outcomes

  1. Function Acquisition Speed Test (FAST)

    Administer the Function Acquisition Speed Test (FAST) to measure how quickly individuals learn associations between stimuli and responses, focusing on emotional biases related to self (e.g., feelings of unworthiness, ridicule) and others (e.g., dependency, validation). The aim is to assess the intensity of emotional biases in BPD patients compared to BD patients and healthy controls.

    Time frame: Measured at baseline

  2. Visual Analogue Scale (VAS) for Perceived Alignment with BPD

    After viewing an educational video explaining Borderline Personality Disorder (BPD) as relational addiction, assess how participants perceive the alignment of their personal experiences with BPD traits, using a Visual Analogue Scale (VAS) ranging from 0 to 10.

    Time frame: Measured at baseline

  3. Love Addiction Inventory (LAI)

    Using the Love Addiction Inventory (LAI), a 24-item self-report scale, to measure symptoms of love addiction. Participants rate their responses on a 5-point Likert scale, with higher scores indicating greater levels of love addiction symptoms, among patients with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD.

    Time frame: Measured at baseline

  4. Beta-Endorphin Levels

    valuate the correlation between beta-endorphin levels and the dimension of relational addiction among patients with BPD, BD, and healthy controls

    Time frame: Measured at baseline

  5. Dysfunctional Self-Perception and Related Indicators (SES)

    Assessing dysfunctional self-perception and its associated indicators-including feelings of emptiness - among BPD group, BD group and HC group, using : * Subjective Emptiness Scale (SES): An 8-item self-report scale measuring feelings of inner emptiness. Higher scores indicate greater perceived emptiness.

    Time frame: Measured at baseline

  6. Dysfunctional Self-Perception and Related Indicators (RSES)

    Assessing dysfunctional self-perception and its associated indicators-including self-esteem-among BPD group, BD group and HC group, using : \- Rosenberg Self-Esteem Scale (RSES): A 10-item self-report scale assessing global self-worth. The total score ranges from 0 to 30, with higher scores indicating higher self-esteem.

    Time frame: Measured at baseline

  7. Dysfunctional Self-Perception and Related Indicators (ESS)

    Assessing dysfunctional self-perception and its associated indicators-including shame,-among BPD group, BD group and HC group, using : \- Experience of Shame Scale (ESS): A 25-item self-report scale covering eight domains of shame experiences, including personal habits, interpersonal behaviors, and body image. Higher scores reflect greater shame experiences.

    Time frame: Measured at baseline

  8. Dysfunctional Self-Perception and Related Indicators (VAS)

    Assessing dysfunctional self-perception and its associated indicators-including shame,-among BPD group, BD group and HC group, using : \- Visual Analog Scale (VAS) for Psychological Pain: Participants mark a point on a 10 cm line that represents their current level of psychological pain. Higher values indicating greater psychological pain.

    Time frame: Measured at baseline

  9. Painful Experiences Related to the Relational Object (MSR)

    Assessing the impact of painful relational experiences, focusing on rejection sensitivity, among patients diagnosed with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD, and healthy controls (HC), using : \- Rejection Sensitivity Scale (MSR): A 9-item self-report scale assessing the level of anxiety and likelihood of perceiving rejection in various interpersonal situations. Higher scores indicate greater sensitivity to rejection.

    Time frame: Measured at baseline

  10. Painful Experiences Related to the Relational Object (ESUL)

    Assessing the impact of painful relational experiences, focusing on loneliness, among patients diagnosed with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD, and healthy controls (HC), using : \- University of Laval Loneliness Scale (ESUL): A 20-item self-report scale measuring perceived loneliness in adults. The scale assesses both emotional and social loneliness. Higher scores indicate greater loneliness.

    Time frame: Measured at baseline

  11. Painful Experiences Related to the Relational Object (RSQ)

    Assessing the impact of painful relational experiences, focusing on attachment styles, among patients diagnosed with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD, and healthy controls (HC), using : \- Relationship Scale Questionnaire (RSQ): A 30-item self-report scale evaluating attachment styles and relational anxiety. Higher scores reflect more insecure attachment styles.

    Time frame: Measured at baseline

  12. Compulsive Sexual Behavior Disorder

    Assessing the severity of compulsive sexual behaviors (CSBD) among patients with Borderline Personality Disorder (BPD) without Bipolar Disorder (BD), those with BD without BPD, and healthy controls (HC), using : \- Compulsive Sexual Behavior Scale (CSBD-19): a 19-item self-report scale that assesses the severity of compulsive sexual behaviors, following the diagnostic guidelines of the ICD-11. The scale evaluates key dimensions of CSBD, including control, salience, relapse, dissatisfaction, and negative consequences. Participants rate the frequency and impact of their sexual behaviors and impulses on a 5-point Likert scale. Higher scores indicate more severe compulsive sexual behavior.

    Time frame: Measured at baseline

  13. Non-Relational Addictive Propensity

    Assessment of Non-Relational Addictive Behaviors in Patients with Borderline Personality Disorder (BPD), Bipolar Disorder (BD), and Healthy Controls (HC), using substance use disorder criteria. Participants will be screened for a range of substances (e.g., alcohol, opioids, stimulants) and will be asked about the frequency, quantity, and impact of substance use in their life.

    Time frame: Measured at baseline

  14. Suicidal Tendencies

    Assessment of Suicidal Tendencies in Patients with Borderline Personality Disorder (BPD), Bipolar Disorder (BD), and Healthy Controls (HC), using : * Columbia-Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a clinician-administered assessment tool designed to measure the severity and frequency of suicidal and para-suicidal behaviors. The scale includes questions about lifetime suicidal ideation, recent suicidal ideation, and behaviors, including planning, attempts, and self-injurious actions.

    Time frame: Measured at baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.

Of 106 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's planned 22 months is below that.

Counting every sponsor, half of 108 studies reached it within 35 months; a quarter within 24 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 13, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07337889
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Jun 1, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jun 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion